The above shows that KB is expected to become a therapeutic drug for ischemic heart disease by affecting the phosphorylation level of AKT/AMPK and regulating Nrf2/ARE/HO-1 signaling. This evidence concerns the gene NFE2L2 and coronary artery disorder.